Impact Factor 6.429

The 5th most cited journal in Immunology

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2018.00943

Dopaminergic Control Of Inflammation And Glycemia In Sepsis and Diabetes.

Eleonora Feketeova1, Zhifeng Li1, Biju Joseph1, Roshan Shah1,  Zoltan Spolarics1 and  Luis Ulloa1, 2*
  • 1Surgery, Medical School, Rutgers, The State University of New Jersey, United States
  • 2Center for Inflammation and Immunity, Medical School, Rutgers, The State University of New Jersey, United States

Most preclinical treatments for sepsis failed in clinical trials in part because the experimental models of sepsis were performed on healthy animals that do not mimic septic patients. Here, we report that experimental diabetes worsens glycemia, inflammation and mortality in experimental sepsis. Diabetes increases hyperglycemia, systemic inflammation and mortality in sepsis. Diabetes exacerbates serum TNF levels in sepsis by increasing splenic TNF production. Both serum from diabetic mice and glucose increase cytokine production in splenocytes. Anti-inflammatory treatments can’t control hyperglycemia and are less effective in diabetic patients. By contrast, dopaminergic agonist type-1, fenoldopam, attenuates hyperglycemia and systemic inflammation in diabetic septic mice by inhibiting splenic p65NF-kB phosphorylation. Fenoldopam inhibits TNF production in splenocytes even at high glucose concentrations and inhibits the canonical NF-kB pathway by inhibiting p65RelA and p50NF-kB1 phosphorylation without affecting the non-canonical NF-kB proteins. Treatment with fenoldopam ‘rescues’ diabetic mice from established polymicrobial peritonitis even when the treatment is started after the onset of sepsis. These results suggest that dopaminergic agonists can control hyperglycemia, systemic inflammation and provide therapeutic advantages for treating diabetic patients with sepsis in a clinically relevant time frame.

Keywords: diabetic sepsis, Inflammation Mediators, Dopaminergic agonist, Murine sepsis models, Phosphorylation

Received: 09 Mar 2018; Accepted: 16 Apr 2018.

Edited by:

Valentin A. Pavlov, The Feinstein Institute for Medical Research, Northwell Health, United States

Reviewed by:

Donald B. Hoover, East Tennessee State University, United States
George Hasko, Columbia University, United States  

Copyright: © 2018 Feketeova, Li, Joseph, Shah, Spolarics and Ulloa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Luis Ulloa, Medical School, Rutgers, The State University of New Jersey, Surgery, Newark, United States, mailforluis@yahoo.com